Breathe Well Live Well
|
Approval given for SkyePharma's asthma treatment
Stock Market Wire StockMarketWire.com – SkyePharma (LSE SKP) has announced that the UK regulatory authority, the Medicines and Healthcare product Regulatory Agency (MHRA), has granted marketing authorisation for flutiform®, a combination product for the treatment of … SKYEPHARMA PLC : Half Yearly Report |
View full post on asthma – Google News
 AARP News |
COPD-asthma market to reach $47bn in 2017
PMLiVE The global market for asthma and chronic obstructive pulmonary disease (COPD) drugs is set to reach $47bn in 2017 according to a new report. US market research firm BCC Research estimates that the market for prescription drugs in these respiratory … Global Markets for Asthma, COPD Drugs to Hit $47 Billion in 2017 Meet held to discuss respiratory diseases Global Markets for Asthma & COPD Drugs to hit $47 Billion in 2017 |
View full post on asthma – Google News
 MedPage Today |
Israel : TEVA bags approval from FDA to market generic asthma treatment …
Equities.com US Food and Drug Administration (FDA) have given its approval to Teva Pharmaceutical Industries Ltd. for generic versions of asthma and allergies treatment Singulair in adults and children. Made by Merck & Co., brand Singulair has $5 billion in annual … New generic Singulair could save asthma sufferers big bucks Generic Singulair Approved FDA approves generic versions of asthma, allergy drug |
View full post on asthma – Google News
 Business Today |
Dr Reddy's launches asthma drug in US market
NDTV Dr Reddy's Laboratories today said it has launched Montelukast Sodium tablets, used for treating asthma and allergies, in the US market after getting approval from the American health regulator. The company received approval from US Food and Drug … Aurobindo gets USFDA nod for asthma drug Aurobindo, Glenmark get US nod for asthma drug Mylan introduces Generic Version of Singulair, Singulair Chewable Tablets |
View full post on asthma – Google News
 Business Standard |
Dr Reddy's launches asthma drug in US market
Business Standard Dr Reddy's Laboratories today said it has launched Montelukast Sodium tablets, used for treating asthma and allergies, in the US market after getting approval from the American health regulator. The company received approval from US Food and Drug … Aurobindo gets USFDA nod for asthma drug Aurobindo, Glenmark get US nod for asthma drug Aurobindo gets US FDA nod for anti-asthma, chewable tablets |
View full post on asthma – Google News
|
Recently Released Market Study: R&D Trends: Asthma – Extensive Investment in …
SBWire (press release) Boston, MA — (SBWIRE) — 07/26/2012 — Datamonitor identified 139 products in development for asthma in 2012. In the near term Datamonitor expects that there will be little change in treatment regimens but strong innovation is seen in earlier stages … |
View full post on asthma – Google News
|
"Asthma Global Clinical Trials Review, H1, 2012" Now Available at Fast Market …
SBWire (press release) Boston, MA — (SBWIRE) — 07/24/2012 — GlobalData's clinical trial report, "Asthma Global Clinical Trials Review, H1, 2012" provides data on the Asthma clinical trial scenario. This report provides elemental information and data relating to the … |
View full post on asthma – Google News
|
Tech and Biotech: Asthmapolis device cleared for market
77Square.com The young company, established in 2010 based on the work of co-founder David Van Sickle, an asthma epidemiologist and honorary associate fellow at the UW-Madison, already has moved to bigger quarters at 612 W. Main St. from its previous offices at 3 S. Tech and Biotech: Anteco is in growth mode |
View full post on asthma – Google News
|
Global asthma and COPD drug market to reach nearly $27 billion in …
The Pharma Letter The global asthma and chronic obstructive pulmonary disease (COPD) market was worth $25.102 billion in 2010, and is expected to reach $26.965 billion in … |
View full post on asthma – Google News
|
Asthma and COPD Drug Market Expected to Reach USD 26965.5 …
MarketWatch (press release) The asthma market is witnessing intense competition due to the increased entry of inhaled corticosteroids, combinational therapies, and beta-agonists. |
View full post on asthma – Google News